| 摘要 |
Methods for the treatment of osteolytic bone disease and for the inhibition of osteoclastogenesis are disclosed. The methods utilize COX-2 inhibitors and/or inhibitors of NF-kappaB activation, administered to patients in an amount effective to inhibit osteoclastogenesis. Also disclosed are methods to modulate the expression of MIP-1alpha in a subject.
|
